FDA's CFS/ME Drug Development Workshop: Day Two: Morning Panels – ProHealth
FDA’s CFS/ME Drug Development Workshop: Day Two: Morning Panels
ProHealth Dr. Montoya: Antivirals, immune modulators. He believes that the immune response to the infectious agent is what drives CFS/ME symptoms, but for some patients it may be too late. Jennie Spotila added Rituximab, as well as drugs that can increase VO2 max. |